10 Years of Ardigen: Voices of Leadership Interview with Livia Legg
What does it take to build lasting partnerships in a field as complex – and as critical – as drug discovery and development?
For Livia Legg, Ardigen’s Chief Commercial Officer, it starts with something simple but rare: trust.
In this special edition of 10 Years of Ardigen: Voices of Leadership, Livia shares what brought her to the company, how Ardigen earns trust in a global, high-stakes industry, and what’s next for AI-powered collaboration in life sciences.
Q: What drew you to Ardigen and what made you believe in its commercial potential?
Livia: I was drawn to Ardigen because it sits at the intersection of science, technology, and purpose. From the beginning, I saw a company with brilliant experts and advanced technology and solutions coupled with a culture that fosters collaboration, curiosity, and integrity. The spirit of working together to solve meaningful problems made it clear this was more than a company, it was a team with a mission. What convinced me of its commercial potential was the clarity of vision: Ardigen is not simply building tools, it is building trust with clients and creating lasting value. That combination is rare, and it is what inspired me to join.
Q: From your perspective, what defines a strong, long-term partnership in the life sciences industry?
Livia: A strong partnership is built on transparency, scientific excellence, and alignment of strategic goals. Life sciences is a high-stakes industry, and clients need partners who can deliver reliably, adapt quickly, and think beyond transactions. For me, trust is the true currency of long-term collaboration. This is measured by the value we create and the impact we make as a partner.
Q: What are the biggest expectations clients have for AI CROs in 2025?
Livia: Clients expect AI CROs to move beyond interesting algorithms and deliver measurable, accelerated outcomes in their pipelines. They seek partners who bring together robust AI capabilities with deep biological insight and a pragmatic approach to integration into drug discovery workflows. Another expectation is scalability; clients want solutions that grow with their needs. Increasingly, they are looking for AI CROs that bring global perspective and credibility in addition to technical know-how.
Q: What makes working with Ardigen a distinct experience for clients?
Livia: Ardigen’s unique approach is to start with the data. In addition to offering advanced tools and technologies, we help clients become AI-ready by leveraging our expertise in the data universe and data infrastructure. This ensures that AI solutions are impactful and scalable within their organizations.
Our clients also tell us that Ardigen feels different because of the people behind the work. We bring scientific rigor and technical excellence, but also curiosity, creativity, and a genuine partnership mindset. It’s this combination of strong data foundations, advanced technology, and dedicated people that makes working with Ardigen a distinct experience.
Q: What’s your approach to growing commercial operations in a company rooted in deep science?
Livia: Growth begins with understanding where the market is headed and how our science can accelerate in a differentiated way. My approach has been to build bridges between our experts and our clients, ensuring our commercial strategy reflects both scientific integrity and market relevance. It is about translating deep expertise into clear value propositions that resonate with clients and position us competitively. Growth comes naturally when you can align those two worlds
Q: You’ve worked with global life science companies – how do you position Ardigen on the international stage?
Livia: We position Ardigen as a global partner that clients rely on to deliver both innovation and impact. As a result, Ardigen is recognized as a leader among the top 5% of AI companies in life sciences worldwide. With experts located across ten countries, we bring international perspective and local insight to every collaboration. Beyond execution, clients look to us for thought leadership including guidance on how to integrate AI effectively into their R&D strategies, anticipate industry shifts, and apply emerging technologies in ways that create real-world value. This combination of trusted partnership, scientific depth, and forward-looking insight is what defines our position on the international stage.
Final question: What would you like the world to remember about Ardigen in another 10 years?
Livia: I would like the world to remember Ardigen as the company that made AI truly meaningful in drug discovery by leveraging advanced technology for the good of human health. I hope people will say, “Ardigen was a partner that mattered. They helped bring life-changing medicines to patients faster.” That legacy of impact, trust, and scientific excellence is what Ardigen will be remembered for.
Livia Legg Chief Commercial Officer
